Research updates
Spain’s ongoing LAMA2-CMD natural history study
In 2022, a natural history study was initiated with LAMA2-CMD patients at Barcelona’s Vall d’Hebron Institute of Research. Natural history…
Research updates
-
![]()
Research updates
-
![]()
News
One step closer: FDA grants Rare Pediatric Disease designation to Modalis Therapeutics’ MDL-101 gene therapy
Modalis Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to…
-
![]()
News
Workshop to establish subtype-specific care recommendations for LAMA2-CMD
We are thrilled to announce a new clinical workshop focused on establishing subtype-specific care recommendations for LAMA2-RD, and using this experience as a prototype to develop recommendations for…
-
![]()
News
Dr. Voermans secures funding for extension of LAMA2-CMD natural history study
In 2022, Dr. Nicol Voermans and her team at Radboud UMC, Netherlands, launched the LASTSTRONG natural history study. With new…
-
![]()
Research updates
Modalis Therapeutics advances a novel gene therapy for LAMA2-CMD
Modalis Therapeutics has made significant strides in developing a gene therapy technology aimed at treating LAMA2-congenital muscular dystrophy (LAMA2-CMD). Earlier…
-
![]()
News
France’s new LAMA2-CMD natural history study
LAMA2-France and Partners launch landmark LAMA2-CMD natural history study in France. The first French natural history study focused on LAMA2-CMD…
The driving forces behind Lama2.com
View all partners
